These have not been systemically examined in SMA, and we hypothesized that CSF proteins involved in inflammation and neuronal activity may better correlate with individual response to SMN1 enhancing therapies than NfL [8–10]. The gene discussed is NEFL; the disease is proximal spinal muscular atrophy.